Fortis Group Advisors LLC Buys 43,213 Shares of Novo Nordisk A/S $NVO

Fortis Group Advisors LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 145.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 72,916 shares of the company’s stock after acquiring an additional 43,213 shares during the quarter. Fortis Group Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,496,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. Godfrey Financial Associates Inc. acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $25,000. WealthCollab LLC boosted its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares during the period. Jackson Grant Investment Advisers Inc. acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $29,000. Transamerica Financial Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 201.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock worth $31,000 after buying an additional 403 shares in the last quarter. Finally, Quaker Wealth Management LLC grew its holdings in shares of Novo Nordisk A/S by 186.0% during the fourth quarter. Quaker Wealth Management LLC now owns 615 shares of the company’s stock worth $31,000 after buying an additional 400 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on NVO shares. Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a research note on Wednesday. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Finally, Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Four equities research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the company. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $64.94.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $45.91 on Friday. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The company has a market cap of $204.99 billion, a P/E ratio of 11.23, a P/E/G ratio of 4.23 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock’s 50-day simple moving average is $47.36 and its 200 day simple moving average is $44.51.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The firm had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a $0.5786 dividend. The ex-dividend date of this dividend is Monday, August 17th. This represents a dividend yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 42.79%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Oral Wegovy adoption is emerging as a potential catalyst. Jim Cramer highlighted accelerating pill prescriptions and argued that Wall Street’s initial negative reaction to Novo’s quarterly performance may have overlooked the company’s underlying strength. Jim Cramer Reevaluates Novo Nordisk as Wegovy Pill Adoption Accelerates
• Positive Sentiment: Unusually high call-option activity suggests some traders are positioning for a rebound: investors purchased roughly 100,752 calls, about 58% above typical volume. This is a market signal rather than a change in fundamentals.
• Positive Sentiment: Novo’s CEO Mike Doustdar said the obesity-drug market will not be dominated by a single company, arguing that patients will value differentiated treatments and that oral options could broaden demand. Novo CEO Says Obesity Market Won’t Be Winner-Take-All Battle With Lilly
• Neutral Sentiment: Zacks Research upgraded Novo Nordisk from “strong sell” to “hold,” indicating reduced bearishness but not a bullish recommendation. Erste Group also issued a fiscal-2026 earnings estimate, though no estimate details were provided.
• Negative Sentiment: Eli Lilly is gaining obesity-drug market share, creating concern that Lilly’s injectable and oral therapies could widen its competitive advantage even as Novo reports record prescriptions for oral Wegovy. Can Novo Nordisk’s GLP-1 Pill Momentum Offset Lilly’s Growing Edge?
• Negative Sentiment: The company’s chief executive acknowledged Lilly’s market-share gains, while an escalating marketing dispute highlights intensifying competition in the strategically important weight-loss market. Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.